Continuous or Intermittent Cetuximab Plus FOLFIRI as First-line Treatment in RAS/BRAF Wild-type mCRC Patients

NCT07004413 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

267

Enrollment

OTHER

Sponsor class

Conditions

Colorectal Cancer Metastatic

Interventions

DRUG: FOLFIRI+cetuximab
DIAGNOSTIC_TEST: Guardant360 ctDNA assay

Sponsor

Charite University, Berlin, Germany

Collaborators

[object Object]
[object Object]